Company / Net Income
Kiniksa Pharmaceuticals International, plc Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$59.0M
FY2025
5-year range
-$161.9M / $183.4M
FY2021-FY2025
Trend
+236.6%
vs FY2024
Sector context
#48 of 216
Health Care
What the data says
Net Income changed +237% YoY in FY2025, a notable deviation from the 8-year average annual change of -21%.
Based on SEC 10-K filings.
$59M in FY2025 with a 3-year CAGR of -31.5%. Top quartile in the Health Care sector.
Improved from $14M to $59M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -31.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 216This company $59.0M Sector average $454.1M
▼
-87.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -31.5%, indicating a declining trend.
- In FY2025, net income increased 236.6% year-over-year.
- Ranks #48 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2022.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.0M | +236.6% |
| FY2024 | -$43.2M | -406.7% |
| FY2023 | $14.1M | -92.3% |
| FY2022 | $183.4M | +213.3% |
| FY2021 | -$161.9M | -0.3% |
| FY2020 | -$161.4M | +0.3% |
| FY2019 | -$161.9M | -56.8% |
| FY2018 | -$103.2M | -59.1% |
| FY2017 | -$64.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026